Acura Pharmaceuticals, Inc. · OTC:ACUR
Acura Pharmaceuticals — Technical Presentation (July 2016)
14 slides from Acura Pharmaceuticals's technical presentation, Jul 13, 2016
Slide 1: Study AP-LTX-400 Subject Level Review
July 14, 2016 Study AP - LTX - 400 Subject Level Review © 2016 Acura Pharmaceuticals, Inc. All Rights Reserved
Slide 2: General Caution Regarding Forward Looking Statements
2 General Caution Regarding Forward Looking Statements Certain statements in this presentation constitute “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forwarding - looking statements involve known and unknown risks, uncertainties an
Slide 3: Study 400 – Subject Level Review
3 Study 400 – Subject Level Review • Outcomes of pH data review • Review of Study 400 Subject Level data • Identification of key patient populations • Conclusions • Next Steps for the LTX - 04 Development Program
Slide 4: Study Design
4 Study 400 – Design 60 subjects enrolled 10 taking 6 tablets 10 taking 4 tablets 10 taking 8 tablets 9 Complete 8 Complete 8 Complete Cohort 2 10 taking 2 tablets 10 taking 1 tablet 10 taking 3 tablets 10 Complete 8 Complete 8 Complete Cohort 1
Slide 5: Objectives and Topline Results
5 Study 400 – Objectives Objectives: • Demonstrate LIMITX technology can retard the release of the active ingredient as 3 or more doses are administered in humans • Demonstrate the LTX - 04 formulation achieves blood levels of drug with 1 and/or 2 tablets equivalent to DILAUDID Topline (Dosing Group
Slide 6: Cmax Change by Subject
6 Study 400 – Cmax Change by Subject • Since the Cmax of LTX - 04P as a group is 53% of DILAUDID, for comparison purposes each subject’s LTX - 04P was adjusted based on the 1 and 2 tablet group average. • To be conservative, each subject’s Cmax of LTX - 04P was multiplied by 2x to compute a percent
Slide 7: Completers % Change in Cmax by Tmax
7 3, 4, 6 & 8 Tablet Completers Study 400 – % Change in Cmax by Tmax • 58% (19 of 33 subjects) had a reduction in Cmax • 74% (14 of the 19) had a Diluadid Tmax of 30 minutes or less
Slide 8: Completers % Change in Cmax by Tmax: Faster and Slower Groups
8 3, 4, 6 & 8 Tablet Completers Study 400 – % Change in Cmax by Tmax • Further analysis identifies a “Faster” absorber group ( Dilaudid Tmax of 30 minutes or less) and a “Slower absorber group • 17 subjects are in the Faster Group and 16 in the Slower Group FASTER Group SLOWER Group
Slide 9: The Faster Group are higher absorbers
9 Study 400 – The Faster Group are higher absorbers 3,4,6 & 8 Tablet Completers C max * (ng/mL) Group Faster mean (SD) Slower mean (SD) Dilaudid 1.97 (1.25) 1.07 (.63) 1.8x LTX - 04P x 2 1.21 (.44) 1.14 (.46) 1.1x N 17 16 Minimum 0.64 0.50 1.3x Median 1.53 0.98 1.6x Maximum 5.27 1.98 2.7x * Dose Adj
Slide 10: Distribution of Cmax Change
10 Study 400 – Distribution of Cmax Change
Slide 11: Tmax Extended for the Faster Group
11 3,4,6 & 8 Tablet Completers Tmax of Dilaudid (hours) Group Faster mean (SD) Slower mean (SD) All mean SD Dilaudid 0.49 (.06) 1.03 (.37) 0.75 (.38) LTX - 04P 0.79 (.51) 0.77 (.73) 0.78 (.63) n 17 16 33 SD=Standard Deviation Study 400 – Tmax Extended for the Faster Group • Tmax for the Faster Group
Slide 12: Subject Level Conclusions
12 Study 400 – Subject Level Conclusions Lengthening of the Tmax for the Faster Absorber Group again confirms that the LIMITx concept works The LTX - 04P showed its best effectiveness in the Faster Absorber Group exhibiting: - 82% of subjects had an estimated reduction in Cmax - 38% average estimate
Slide 13: LTX-04 Path Forward
13 • Reformulation of micro - particles for faster release continues • Meet with FDA under FAST TRACK • Expect to run the next clinical study in 4Q 2016 LTX - 04 Path Forward
Slide 14: Acura Pharmaceuticals, Inc. contact details
Acura Pharmaceuticals, Inc. 616 N. North Court, Suite 120 Palatine, IL 60067 (847) 705 - 7709 www.AcuraPharm.com www.Nexafed.com www.Oxaydo.com
Acura Pharmaceuticals — Technical Presentation (July 2016) on 6ix